PK/PD study of ceftazidime/avibactam in patients with severe intra-abdominal infections treated by continuous veno–venous hemofiltration

Sai Tian, Yong Chen, Mingjie Qiu, Wenqi Wu, Lei Dou, Jiajie Wang, Li Xu, Zhitao Zhou, Meilin Wu, Jiayang Li, Xiuwen Wu, Jianan RenResearch Square 2025 · DOI

TL;DR

This study reveals that continuous veno–venous hemofiltration (CVVH)—a common life-support treatment for critically ill patients—significantly accelerates the clearance of the antibiotic combination ceftazidime/avibactam. Using Monte Carlo simulations, the researchers demonstrate that standard dosing regimens may fail to reach therapeutic targets for resistant pathogens, necessitating individualized dosing based on specific bacterial susceptibility (MIC).

What Problem Does This Paper Address?

In the ICU, patients with severe intra-abdominal infections (sIAI) often face a "perfect storm" of medical challenges: life-threatening infections, acute kidney injury, and the need for Continuous Renal Replacement Therapy (CRRT). Ceftazidime/avibactam (CZA) is a powerful weapon against multidrug-resistant Gram-negative bacteria, but because it is primarily eliminated by the kidneys, its behavior in the body changes drastically when a patient is on a dialysis-like machine like CVVH.

The challenge is a balancing act. Too little drug leads to treatment failure and antibiotic resistance; too much can cause neurotoxicity or further organ damage. Currently, there is a lack of clear, evidence-based dosing guidelines for CZA specifically tailored to patients undergoing CVVH, leaving clinicians to rely on guesswork or "one-size-fits-all" protocols.

Methods

The researchers conducted a prospective study at Jinling Hospital involving seven patients with sIAI who were receiving CVVH.

  1. Pharmacokinetic (PK) Sampling: The team collected blood samples at specific intervals (pre-dose and 2, 3, 4, 6, and 8 hours post-dose) both during CVVH treatment and at least 24 hours after it was discontinued.
  2. Drug Quantification: Plasma concentrations were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
  3. Monte Carlo Simulations (MCS): To predict how different dosing regimens would perform across a broader population, they ran 10,000 simulations. They tested four intravenous regimens (ranging from 750mg/187.5mg to 3000mg/750mg every 8 hours) against two clinical targets:
  4. Standard Target: 100% of the time, the free drug concentration stays above the Minimum Inhibitory Concentration (MIC).
  5. Intensive Target: 100% of the time, the concentration stays above four times the MIC (for ceftazidime) to maximize efficacy against highly resistant strains.

Datasets

The study utilized two primary data sources:

  • Clinical Cohort: Original PK data from 7 enrolled patients (5 men, 2 women) with a mean age of 56.4 years.
  • Microbiological Data: MIC distributions for Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa were pulled from the EUCAST (European Committee on Antimicrobial Susceptibility Testing) database (accessed March 2025) to evaluate the Cumulative Fraction of Response (CFR).

Key Insights and Ideas

  • CVVH is a Clearance Engine: The most striking insight is that CVVH doesn't just "replace" kidney function; it significantly enhances the clearance of CZA compared to the patient's baseline state of renal failure. Clearance rates for both drugs more than doubled during CVVH sessions.
  • The "Standard" vs. "Intensive" Gap: While standard dosing (2000mg + 500mg q8h) works well for common susceptible bacteria (MIC ≤ 8 mg/L), it falls short when facing "intensive" targets or highly resistant pathogens.
  • Hydrophilicity Matters: Because ceftazidime and avibactam are highly hydrophilic (water-loving) and have low molecular weights, they are "sieved" out of the blood by CVVH membranes very efficiently. This explains why the machine has such a profound impact on drug levels.
  • Individualization is Mandatory: The study argues against empirical dosing. Because the machine's settings (flow rates) and the patient's remaining kidney function vary so much, dosing must be "individualized" based on the specific pathogen's MIC.

Key Results

  • Clearance (CL) Spikes: During CVVH, the clearance of ceftazidime rose to 2.46 L/h (vs. 0.9 L/h outside CVVH), and avibactam rose to 2.89 L/h (vs. 1.09 L/h).
  • Target Attainment (PTA):
    • During CVVH, all tested regimens achieved >90% PTA for pathogens with an MIC ≤ 8 mg/L (standard target).
  • For the intensive target, only the highest dose (3000mg + 750mg q8h) was effective, and even then, only for pathogens with an MIC ≤ 2 mg/L.
  • CFR for P. aeruginosa: The 2000mg and 3000mg regimens achieved an "optimal" response (>90% CFR) for P. aeruginosa under standard targets, but no regimen was considered optimal for the intensive target.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small Sample Size: With only seven patients, the results provide a strong signal but require validation in larger cohorts.
  • Single CRRT Mode: The study focused exclusively on CVVH. Other modes, like continuous veno-venous hemodialysis (CVVHD), might yield different PK profiles.
  • Residual Renal Function: Most patients were oliguric (producing little urine), so the study could not fully account for the role of the patients' own remaining kidney function in drug clearance.
  • Safety: While higher doses were simulated to meet PK/PD targets, the clinical safety (e.g., neurotoxicity risk) of these intensified regimens was not evaluated.

Future research should explore multiple CRRT modes and incorporate real-time therapeutic drug monitoring (TDM) to refine these dosing models in clinical practice.

Summary updated

Abstract

<title>Abstract</title> <bold>Purpose:</bold> To investigate the pharmacokinetics (PK) of ceftazidime/avibactam and optimize dosing regimens in patients with severe intra-abdominal infection (sIAI) receiving continuous veno–venous hemofiltration (CVVH). <bold>Methods:</bold> Seven patients with sIAI treated with ceftazidime/avibactam and CVVH were enrolled. Blood samples were collected at pre-dose and post-dose (2, 3, 4, 6, and 8 h) during hemodynamic stability. Plasma concentrations were measured, and PK parameters were calculated. Monte Carlo simulations (MCSs) were used to assess the probability of target attainment (PTA) and cumulative fraction of response (CFR) for different dosing regimens. <bold>Results:</bold> CVVH increased the clearance (CL) significantly (ceftazidime: 2.46 ± 0.29 <italic>vs</italic> . 0.9 ± 0.11 L/h; avibactam: 2.89 ± 0.41 <italic>vs</italic> . 1.09 ± 0.08 L/h, <italic>p</italic> &lt; 0.001). For the target of 100%fT ≥ MIC + 100%fT ≥ C <sub>T = 1.0 mg/L</sub> , during CVVH, PTA &gt; 90% at MIC ≤ 8 mg/L. Outside CVVH, PTA &gt; 90% at MIC ≤ 16 mg/L, and only 3000 mg + 750 mg q8h achieved PTA &gt; 90% at MIC = 64 mg/L. For the target of 100%fT ≥ 4× MIC (ceftazidime) + 100%fT ≥ C <sub>T = 4.0 mg/L</sub> (avibactam), during CVVH, PTA &gt; 90% at MIC ≤ 2 mg/L. Outside CVVH, PTA &gt; 90% at MIC ≤ 4 mg/L, and only 3000 mg + 750 mg q8h achieved PTA &gt; 90% at MIC = 16 mg/L. No regimen met the optimal dosing criteria for this target. <bold>Conclusion:</bold> CVVH enhanced the CL significantly. Dosing should be “individualized” based on the MIC and patient-specific factors.
BibTeX
@inproceedings{tian2025pk,
  author = {Sai Tian and Yong Chen and Mingjie Qiu and Wenqi Wu and Lei Dou and Jiajie Wang and Li Xu and Zhitao Zhou and Meilin Wu and Jiayang Li and Xiuwen Wu and Jianan Ren},
  title = {{PK/PD study of ceftazidime/avibactam in patients with severe intra-abdominal infections treated by continuous veno–venous hemofiltration}},
  booktitle = {Research Square},
  year = {2025},
  doi = {10.21203/rs.3.rs-7319086/v1},
}
Figure